-
Featured Authors
-
Archives
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
-
Meta
Monthly Archives: November 2011
The Ethics of Global Clinical Trials
By Dr. Russell Medford, Salutria Pharmaceuticals Recent reports have raised concerns about how clinical trials are being performed in other countries, particularly in the developing world. Even prior to these reports, some have asserted that sponsors conduct clinical trials abroad to avoid red tape and avoid overly stringent and time consuming regulatory processes. However, research done by companies with the intent of seeking FDA approval and access to the U.S. market must still meet FDA standards Read More >
World Pneumonia Day: November 12
November 12 marks World Pneumonia Day, a campaign to educate the public about this disease and to advocate for global action to treat and prevent it. Pneumonia is the leading cause of death globally for children under the age of 5, claiming the lives of more than 1.5 million children annually. Pneumonia is also largely a vaccine-preventable disease. Since the introduction of pneumococcal vaccines in the U.S. in 2000, morbidity and mortality from pneumonia have Read More >
Foundation Fighting Blindness Invests in Gene Therapy Research Projects
Recently, the Foundation Fighting Blindness announced an $8.25 million investment in six new gene therapy research projects targeted to have treatments ready for clinical trials within three years. The projects include the following: The Institut de la Vision in Paris and the Friedrich Miescher Institute in Basel, Switzerland, are developing a gene therapy that may revive degenerating cones and potentially enable them to regain their ability to respond to light and provide vision. The treatment Read More >
e-Advocacy: Getting Your 15 MB of Fame
By Seth Ginsberg, co-founder and President of the Global Healthy Living Foundation Advocacy used to be serious. Now it is social. Advocacy used to be Jerry Lewis asking us to open our wallets every Labor Day weekend or he was going to cry, and we did and he did. Today it is us and our friends asking each other to click a box saying “Like” or fire off 140 characters to our followers, or to Read More >
BIO’s Prometheus v. Mayo Amicus Brief Filed
BIO filed an amicus brief in the Prometheus v. Mayo Clinic case. In this case the Supreme Court is being asked to decide whether diagnostic and personalized medicine claims that depend on a correlation of observed phenomena should be excluded from the patent system at the outset, as patent-ineligible abstract ideas or “laws of nature.” BIO’s brief argues that these judicially-created exclusions from patent-eligibility have traditionally been used only under narrow circumstances, and that their Read More >
